FDA Accepts QTORIN Rapamycin Application for Review
The FDA will decide by February 2027 if the drug becomes the first treatment for microcystic lymphatic malformations.
Updated on Oct. 28, 2026 in Cancer
Live Poll
Do you believe access to new therapies for rare diseases is improving in the U.S.?
The FDA has accepted the New Drug Application for QTORIN rapamycin anhydrous gel and granted it Priority Review. This potential treatment for microcystic lymphatic malformations currently lacks any FDA-approved alternatives.
Why it matters
If approved, this therapy would provide the first dedicated medical treatment for patients suffering from microcystic lymphatic malformations. These conditions affect an estimated 30,000 people across the United States.
The New Drug Application for the 3.9% rapamycin anhydrous gel is supported by Phase 3 SELVA study findings that met six prespecified efficacy endpoints. The FDA target action date is set for February 28, 2027.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
Palvella Therapeutics
Headquartered in Wayne, Pennsylvania, this company develops therapies for serious, rare genetic skin diseases.
The details
QTORIN rapamycin has received Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA. Development of the gel is further supported by grant funding from the FDA Office of Orphan Products Development.
Timeline
October 28, 2026: FDA announced acceptance and priority review of the NDA.
February 28, 2027: PDUFA target action date for FDA decision.
First half of 2027: Potential U.S. commercial launch of QTORIN rapamycin.
Health Landscape
This application follows the regulatory framework set by the FDA Orphan Drug Act to incentivize research into rare conditions with no existing standard of care. It marks a significant milestone in specialized dermatological medicine for rare genetic disorders.
Patients currently dealing with microcystic lymphatic malformations may soon have access to the first FDA-approved therapy for their condition. The potential commercial launch in early 2027 could shift the standard of care for the estimated 30,000 affected individuals.
The takeaway
This news highlights the ongoing push to provide medical options for rare diseases through specialized regulatory pathways. Patients and caregivers should track the February 2027 FDA decision to understand future treatment availability.
What happens next
The FDA is scheduled to reach a decision on the New Drug Application by the PDUFA target action date of February 28, 2027.
Further reading
Learn more about the latest developments in Cancer research and treatments.
Live Poll
Do you believe access to new therapies for rare diseases is improving in the U.S.?
